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Eczema, a type of persistent itchy skin rash, 
in children may be an early manifestation of 
allergic disease (Leung et al. 2004). Although 
exposure to allergens may be important in the 
development of eczema, exposure to other 
environmental agents has been implicated as 
well. For example, in cross-sectional studies, 
exposure to environmental tobacco smoke, 
airborne propylene glycol, glycol ether, and 
residential renovation around the time of 
birth have been associated with eczema in 
young children (Choi et al. 2010; Herbarth 
et al. 2006; Kramer et al. 2004). Results from 
a 2003 U.S. national survey suggest that liv-
ing in urban areas, African-American race, 
higher parental education, and child-care 
attendance are associated with an increased 
prevalence of childhood eczema (Shaw et al. 
2011). Further, not all childhood eczema as 
defined by the World Allergy Organization 
(Johansson et al. 2004) is allergic in origin. 
Either allergic or nonatopic eczema (i.e., 
intrinsic or nonallergic eczema/dermatitis) 
may develop. The two phenotypes differ 
somewhat in their risk factors and in their 
immunopathogenesis (Kusel et al. 2005).
Some phthalates are added to plastics to 
increase flexibility and are common compo-
nents of many plastic household products; oth-
ers, such as butylbenzyl phthalate (BBzP), are 
added to vinyl floorings. BBzP is found fre-
quently in house dust and indoor air (Adibi 
et al. 2008; Kolarik et al. 2008a). Monobenzyl 
phthalate (MBzP), the main BBzP metabo-
lite, was detected in greater than 97% of urine 
samples in the U.S. 1999–2000 National 
Health and Nutrition Examination Survey 
(NHANES) (Silva et al. 2004) and detected 
in a pilot study (n = 11) from amniotic fluid in 
Germany (Wittassek et al. 2009). Although diet 
is believed generally to be the largest contribu-
tor to BBzP exposure in adults (Wormuth et al. 
2006), we reported that concentrations of BBzP 
collected in 48-hr personal air samples during 
pregnancy from participants in the Columbia 
Center for Children’s Environmental Health 
(CCCEH) were correlated with concentra-
tions of MBzP in spot urine samples (rS = 0.48, 
p < 0.05, n = 62) (Adibi et al. 2008). Hence, 
non dietary routes, including inhalation and 
dust exposure through skin and ingestion, also 
may be important.
In addition, concentrations of BBzP in 
bedroom dust in a Swedish study were signifi-
cantly higher among children 3–8 years of age 
with physician-confirmed persistent eczema 
and rhinitis (n = 198) versus healthy children 
(n = 202) with a positive dose–response trend in 
the odds ratio (OR) across quartiles of exposure. 
Polyvinyl chloride (PVC) flooring, considered 
an important source of phthalate plasticizers 
in the home, also was associated with persis-
tent allergic symptoms (Bornehag et al. 2004). 
Consistent findings were reported by a study 
of 100 cases and 77 nonsymptomatic control 
children 2–7 years of age in Bulgaria. BBzP 
concentrations were higher in the house dust of 
children with wheeze, rhinitis, or eczema in the 
preceding 12 months, but the difference was 
not statistically significant (mean = 0.38 mg/g 
dust vs. 0.32 mg/g dust, p = 0.35) (Kolarik 
et al. 2008b). Although these findings suggest a 
role of BBzP in the development of eczema, the 
use of urinary biomarkers offers a more direct 
measure of individual exposure than house dust 
by integrating ingestion, inhalation, and dermal 
absorption. In addition, longitudinal studies 
may offer further insight into the timing of 
exposure relative to disease onset.
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Background: Recent cross-sectional studies suggest a link between butylbenzyl phthalate (BBzP) 
in house dust and childhood eczema.
oBjectives: We aimed to evaluate whether concentrations of monobenzyl phthalate (MBzP), 
the main BBzP metabolite in urine, during pregnancy are associated prospectively with eczema in 
young children, and whether this association varies by the child’s sensitization to indoor allergens or 
serological evidence of any allergies.
Methods: MBzP was measured in spot urine samples during the third trimester of pregnancy from 
407 African-American and Dominican women residing in New York City in 1999–2006. Repeated 
questionnaires asked mothers whether their doctor ever said their child had eczema. Child blood 
samples at 24, 36, and 60 months of age were analyzed for total, anti-cockroach, dust mite, and 
mouse IgE. Relative risks (RR) were estimated with multivariable modified Poisson regression. 
Analyses included a multinomial logistic regression model for early- and late-onset eczema versus no 
eczema through 60 months of age.
results: MBzP was detected in > 99% of samples (geometric mean = 13.6; interquartile range: 
5.7–31.1 ng/mL). By 24 months, 30% of children developed eczema, with the proportion higher 
among African Americans (48%) than among Dominicans (21%) (p < 0.001). An interquartile 
range increase in log MBzP concentration was associated positively with early-onset eczema (RR 
= 1.52 for eczema by 24 months; 95% confidence interval: 1.21, 1.91, p = 0.0003, n = 113 report-
ing eczema/376 total sample), adjusting for urine specific gravity, sex, and race/ethnicity. MBzP 
was not associated with allergic sensitization, nor did seroatopy modify consistently the MBzP and 
eczema association.
conclusions: Prenatal exposure to BBzP may influence the risk of developing eczema in early 
childhood.
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The purpose of this study was to investi-
gate whether prenatal measures of BBzP are 
associated with eczema and sensitization to 
common indoor aeroallergens in early child-
hood in an urban birth cohort. We hypoth-
esized that prenatal BBzP would be associated 
with increased risk of eczema and elevated 
indoor allergen specific and total immuno-
globulin (Ig) E.
Methods
As part of the CCCEH birth cohort, 
727 nonsmoking pregnant Dominican and 
African-American women were fully enrolled 
during the third trimester, and mother–child 
pairs were followed prospectively (Perera et al. 
2003). Participant mothers for the present 
analysis (n = 407) had prenatal urinary phtha-
late metabolites measured and responded to 
at least one questionnaire on eczema when 
the child age was between 3 and 60 months. 
The study was approved by the institutional 
review boards (IRBs) of Columbia University 
and the Centers for Disease Control and 
Prevention (CDC). The mother provided 
informed signed consent at time of enroll-
ment in accordance with IRB requirements.
Spot urine samples were collected dur-
ing the third trimester [mean gestational age, 
34 weeks, interquartile range (IQR) 32–36 
weeks] from 1999 through 2006. Samples 
were stored at –80°C until overnight ship-
ment with dry ice to the CDC, where 
they were stored at –70°C until being ana-
lyzed for metabolites of BBzP and several 
other phthalates at the National Center for 
Environmental Health (Adibi et al. 2008; 
Kato et al. 2005). A correction factor of 0.72 
was applied to the MBzP concentrations to 
adjust for previous overestimations of the ana-
lytic standards (CDC 2012). Two metabolites 
of other phthalates, mono-n-butyl phthalate 
and mono(2-ethyl-5-hydroxyhexyl) phthalate, 
known to correlate moderately with MBzP, 
also were considered in two-metabolite co-
pollutant models. The specific gravity of the 
urine was measured after thaw using a hand-
held refractometer (PAL 10-S; Atago USA, 
Bellevue, WA).
Eczema was assessed by questionnaires 
administered to the mother by telephone and 
in-person at repeated visits by asking “Has 
your doctor ever said that your child has 
eczema?” Four questionnaires were adminis-
tered in each of the first 2 postnatal years and 
another four questionnaires between child 
ages 24 and 60 months (for a maximum of 
12 questionnaires). Two-thirds of partici-
pants answered at least 9 questionnaires over 
the 12 possible time points. When the child 
was 60 months, the International Study of 
Asthma and Allergies in Childhood (ISAAC) 
eczema module (Asher et al. 1995) also asked 
“Has your child ever had an itchy rash which 
was coming and going for at least 6 months?” 
and among those who responded positively 
“Has your child had this itchy rash at any 
time in the last 12 months?”
Sera were collected from the children 
at 24, 36, and 60 months of age. Because 
the odds of eczema were higher among chil-
dren 24–36 months of age who developed 
IgE responses specifically against cockroach 
and mouse allergens (but not total IgE), and 
anti-cockroach IgE correlated closely with 
total IgE at 24 and 36 months of age (Chang 
et al. 2010; Donohue et al. 2008), sensiti-
zation to indoor allergens was defined as a 
positive (≥ 0.35 IU/mL) specific IgE to cock-
roach, dust mite, or mouse in any available 
sample by ImmunoCAP (Phadia, Uppsala, 
Sweden). To capture any seroatopy as well, 
total IgE was measured by either immunora-
diometric assay (Diagnostics Products Corp, 
Los Angeles, CA) or by ImmunoCAP, as 
described (Donohue et al. 2008).
Statistical analysis. We compared descrip-
tive statistics among data subsets with t-tests 
and chi-square tests for continuous and cat-
egorical variables, respectively. Urinary con-
centrations of MBzP were log transformed 
before analysis. Specific gravity was retained as 
a covariate in all models to account for varia-
tion in urinary dilution (Barr et al. 2005). Sex 
and race/ethnicity were included as covariates 
in all models as a priori potential confound-
ers. A series of other potential confounders 
[prenatal exposure to environmental tobacco 
smoke, and maternal attributes (age, educa-
tion, marital status, self-report of asthma, 
log total IgE)] were tested sequentially for 
inclusion in the final model based on a > 10% 
change in the parameter estimate for the asso-
ciation of MBzP and early-onset eczema. One 
participant with a concentration of MBzP 
below the limit of detection (0.22 ng/mL; 
specific gravity 1.005) was excluded from 
further analysis because imputing a concen-
tration of half the limit of detection and sub-
sequent log transformation of the predictor 
created an influential point in the regression. 
Sensitivity analysis showed that parameter 
estimates excluding this sample did not differ 
from those in which 1 ng/mL was added to all 
concentrations before log transformation.
We used a modified Poisson regression to 
generate relative risk (RR) and variance esti-
mates for dichotomous outcomes (i.e., eczema, 
sensitization to indoor allergens) (Zou 2004). 
Eczema was reclassified as early-onset eczema if 
it was reported on any questionnaire through 
24 months of age. This combined variable 
for early-onset eczema was restricted to chil-
dren with at least one of four questionnaires 
in the first year, and one of four in the second 
year (n = 376). Eczema was reclassified as late-
onset eczema if the first report of ever eczema 
was reported between age 24 months and 
60 months among participants who completed 
at least one of four questionnaires in the first 
year, one of four in the second year, and one 
of four in the third through fifth year. A multi-
nomial logistic regression was used to estimate 
associations between MBzP and  early-onset 
eczema or late-onset eczema, with no eczema 
through age 60 months as the referent out-
come, among participants who remained 
enrolled through 60 months (n = 339).
Data on indoor allergen sensitization 
using specific IgE were available for 94% of 
children in the early-onset eczema analysis 
(n = 355) and total IgE at 60 months of age 
was available for 78% (n = 295). Although 
the RR regression was a multiplicative model, 
potential interactions between risk factors were 
tested as a departure from additivity using the 
relative excess risk due to interaction (RERI) 
(Rothman et al. 2008), with 95% confidence 
intervals (CIs) from percentiles of 10,000 
bootstrap samples (Knol et al. 2007). Linear 
regression was used for modeling log-trans-
formed total IgE as a continuous outcome.
Statistical analyses were conducted 
using R statistical software (version 2.13.0; 
R Development Core Team, Vienna, Austria) 
where p < 0.05 was considered statistically 
significant.
Results
Cohort characteristics. Participants included 
in analyses did not differ in major demo-
graphic characteristics from the remainder of 
the CCCEH cohort, except for lower prena-
tal exposure to environmental tobacco smoke 
(31% vs. 39%) and sensitization to indoor 
allergens at 24 months (8% vs. 17%); however, 
indoor allergen-specific sensitization did not 
differ at 36 or 60 months or when measures 
from any of the three ages (24, 36, 60 months) 
among available samples for specific IgE were 
combined and comparisons between the two 
groups were reanalyzed (Table 1). MBzP was 
detected in all except one urine sample, and 
concentrations ranged widely [geometric mean 
(GM) = 13.6, IQR: 5.7–31.1 ng/mL]. MBzP 
concentrations were higher among African 
American (GM = 18.3; IQR: 8.7–35.4 ng/mL) 
than Dominican mothers (GM = 11.7, IQR: 
4.9–26.4 ng/mL) (p < 0.001).
Eczema characteristics. By child age 24 
months, 30% of mothers had reported at least 
once that their doctor had ever said that their 
child had eczema, with a higher proportion 
among African-American (48%, n = 62/129) 
than Dominican (21%, n = 51/247) chil-
dren. The proportion of Dominican mothers 
reporting eczema in their children was com-
parable among mothers completing question-
naires in English versus Spanish. There was 
no significant difference in the proportion of 
children with ever-eczema by child sex overall 
(32% female, 28% male, p = 0.37) or after 
Prenatal butylbenzyl phthalate and early eczema
Environmental Health Perspectives • volume 120 | number 10 | October 2012 1477
stratifying by race/ethnicity (data not shown). 
The proportion of children with ever eczema 
generally increased with the child’s age, from 
10% at 3 months to 28% at 60 months 
(Figure 1). However, women were sometimes 
inconsistent in their report of their child’s 
eczema. Among those who had a positive 
report of ever-eczema (at any of the 12 ques-
tionnaire time points), 59% of subsequent 
questionnaires were also positive.
MBzP and eczema. Adjusted RRs of child 
ever-eczema for an IQR increase in prena-
tal MBzP urinary concentrations at each of 
12 questionnaire time points were consistently 
positive with larger magnitudes at the earlier 
ages (Figure 1). Using a reclassified defini-
tion of early onset eczema, an IQR increase in 
log MBzP was associated positively with any 
report of eczema by 24 months (RR = 1.52; 
95% CI: 1.21, 1.91; p < 0.001, n = 113/376) 
after adjusting for specific gravity, sex, and 
race/ethnicity. The parameter estimate for 
child’s sex was not significant (RR = 0.82 
for males vs. females; 95% CI: 0.60, 1.10). 
Adjusting for prenatal exposure to environ-
mental tobacco smoke, or maternal attributes 
(age, education, marital status, self-report of 
asthma, log total IgE) changed the main effect 
of MBzP by < 2%, and these variables were 
not retained in the adjusted model. ORs from 
a three-outcome multinomial logistic regres-
sion model were comparable for ever-eczema 
among inconsistent reporters (who said no 
ever-eczema after having said yes ever-eczema) 
(OR = 1.98; 95% CI: 1.23, 3.17; n = 63) 
and consistent reporters (OR = 2.02; 95% 
CI: 1.19, 3.43; n = 50) compared with those 
who never reported eczema (n = 263). A sec-
ond sensitivity analysis defined the outcome 
for consistent reporters to those with three 
or more consecutive positive reports among 
those with earlier first report of eczema 
(OR = 2.25; 95% CI: 1.22, 4.13 vs. never 
eczema, and OR = 1.90; 95% CI: 1.23, 2.95 
for inconsistent or < 3 positive reports vs. 
never eczema). To determine whether the 
association between an IQR increase in pre-
natal log MBzP concentrations and eczema 
was greater among children with early onset 
(by 24 months) versus late-onset eczema, 
multinomial analyses were performed after 
reclassifying eczema as early (29%, n = 100), 
late (13%, n = 43), or none (58%, n = 196). 
MBzP concentration was associated with early 
onset eczema (adjusted OR = 1.91; 95% CI: 
1.23, 2.97). There was no association between 
MBzP and late onset eczema (adjusted OR = 
0.90; 95% CI: 0.51, 1.58) for an IQR change 
in log MBzP from the multinomial logistic 
regression analysis. Moreover, there was no 
association in a modified Poisson regression 
model between MBzP concentration and the 
report at 60 months of “itchy rash at any time 
in the past 12 months that was coming and 
going for at least 6 months” (RR = 1.23; 95% 
CI: 0.81, 1.88; n = 56/341).
MBzP and eczema by ethnicity. Because 
previously we reported that eczema may vary 
by race/ethnicity (Donohue et al. 2008), we 
sought to understand better whether the asso-
ciation between phthalates and eczema was 
modified by race/ethnicity. Maternal African-
American race versus Dominican ethnicity was 
a significant predictor of report of eczema by 
24 months (RR = 2.09; 95% CI: 1.53, 2.86; 
p < 0.001) after adjusting for MBzP concen-
tration, specific gravity, and sex. There was a 
consistently higher probability of eczema for 
African Americans across the range of urinary 
concentrations of MBzP. Both ethnic groups 
had similar slopes for the exposure–response 
curve in stratified analysis, indicating a lack of 
multiplicative interaction (Figure 2). However, 
there was a nonsignificant greater than additive 
interaction between African American ethnic-
ity and each IQR increase in MBzP urinary 
concentration (RR African American 2.47; 
RR IQR MBzP 1.60; joint RR 3.59; RERI 
0.52; bootstrap 95% CI: –0.11, 1.31).
MBzP, eczema, and allergic sensitiza-
tion. A total of 26% (n = 91/355) of chil-
dren were classified as sensitized to indoor 





n = 320 p-Value
Mother’s age [mean (IQR)]c 25 (21–29) 25 (21–29) 0.13
Mother’s ethnicity (%) 0.46
African American 34 37
Dominican 66 63
Mother completed high school, GED, or greater (%) 63 66 0.45
Never married (%) 66 66 1.00
Prenatal ETS exposure (%)d 31 39 0.03
Maternal asthma (%) 25 19 0.10
Maternal total IgE > 80 IU/mL (%) 36 34 0.74
Child’s sex (% male) 48 48 1.00
Child’s indoor allergic sensitization (%)e
At 24 months 8 17 0.01
At 36 months 14 15 0.82
At 60 months 26 24 0.79
At any of the three ages (24, 36, or 60 months) 26 29 0.44
Abbreviations: ETS, environmental tobacco smoke; GED, General Educational Development; GM, geometric mean.
aMissing: maternal total IgE (n = 143), child’s indoor allergic sensitization at 24 months (n = 136), 36 months (n = 116), 
60 months (n = 93), combined time points (n = 40). bMissing: education (n = 14), never married (n = 6), maternal total 
IgE (n = 129), child’s indoor allergic sensitization at 24 months (n = 143), 36 months (n = 153), 60 months (n = 147), at 
any of the three ages (i.e., measures from 24, 36, or 60 months among children with any available specific IgE levels; 
n = 95). cAssessed with Wilcoxon rank-sum test. dPrenatal ETS exposed if maternal or cord blood cotinine concentra-
tion ≥ 15 ng/mL (available for n = 391 and n = 306, respectively) or report of a smoker in the home on prenatal question-
naire. eIndoor allergic sensitization defined as ≥ 0.35 IU/mL specific IgE to cockroach, dust mite, or mouse.
Figure 1. Relative risk estimates of child ever-eczema for an IQR increase in prenatal log MBzP urinary 
concentration (IQR is 1.7 log units, 5.7–31.1 ng/mL), adjusting for specific gravity, race/ethnicity, and sex 
from separate modified Poisson regression models using questionnaire data collected in person or by 
telephone interview at 12 different ages.
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aeroallergens at 24, 36, or 60 months of age. 
Among children with eczema by 24 months, 
29% (n = 31/106) were sensitized compared 
with 24% among children without eczema 
(n = 60/249) (p = 0.31). Children with 
eczema by 24 months on average had higher 
total IgE levels at 60 months of age than chil-
dren without eczema, regardless of whether 
they were defined as nonsensitized (GM = 
39 IU/mL, n = 67 vs. 24 IU/mL, n = 152; 
p = 0.016) or sensitized to indoor aeroaller-
gens (GM = 207 IU/mL, n = 22 vs. 107 IU/
mL, n = 50; p = 0.056).
There was no observed association between 
an IQR increase in prenatal log MBzP urinary 
concentration and sensitization to indoor 
aeroallergens (RR = 0.89; 95% CI: 0.68, 
1.16, n = 355), adjusting for specific grav-
ity, race/ethnicity, and sex. Similarly, there 
was no observed association between an IQR 
increase in log MBzP concentration and log 
total IgE at 60 months in adjusted analyses 
(β = –0.14; 95% CI: –0.41, 0.13, n = 306). 
We also examined whether the association 
between prenatal MBzP urinary concentra-
tion and eczema differed by sensitization to 
any of three indoor aeroallergens. There was 
no significant interaction between sensitiza-
tion to indoor allergens and higher MBzP 
concentration in predicting eczema using the 
RERI to test for departures from additivity 
(RR sensitization 1.19; RR IQR MBzP 1.54; 
joint RR 1.87; RERI 0.14; bootstrap 95% 
CI: –0.34, 0.42). Retesting the RERI while 
examining interactions between any seroatopy 
(i.e., using total IgE as a continuous variable) 
and higher MBzP concentration in predicting 
eczema found a slightly greater than addi-
tive effect of MBzP and log total IgE at 60 
months of age (RR log total IgE 1.18; RR 
IQR MBzP 1.46; joint RR 1.72; RERI: 0.07; 
95% CI: 0.01, 0.46; n = 295).
Other phthalates and eczema. Although 
urinary concentrations of the metabolites of 
several other phthalates correlated moderately 
with MBzP, in adjusted models with both 
prenatal MBzP and mono-n-butyl phthalate 
(MnBP; a major metabolite of di-n-butyl 
phthalate and a minor metabolite of BBzP) 
or mono(2-ethyl-5-hydroxyhexyl) phthalate 
[MEHHP; a metabolite of di(2-ethylhexyl) 
phthalate (DEHP)] urinary concentrations, 
the estimate for MBzP was changed by 
< 10%. In these two-metabolite models, only 
MBzP was a significant predictor of report 
of eczema by 24 months (RR per log unit 
MnBP = 1.13; 95% CI: 0.89, 1.43; n = 376; 
RR per log unit MEHHP = 1.06; 95% CI: 
0.75, 1.51; n = 376) adjusting for log MBzP, 
specific gravity, race/ethnicity, and sex.
Discussion
We report here a novel association between 
prenatal urinary concentrations of MBzP, 
the main metabolite of BBzP, and the sub-
sequent report of childhood eczema among 
African-American and Dominican children 
in New York City. The association appeared 
to be primarily among those with early-
 onset eczema, reported by 24 months of age. 
Although the proportion of children with 
eczema was higher in African Americans than 
in Dominicans, in both groups there was a 
similar positive association between prenatal 
urinary concentrations of MBzP and early-
onset eczema. No association was observed 
between prenatal urinary concentration of 
MBzP and sensitization to three indoor aller-
gens or total IgE. The association of MBzP 
and eczema was not modified by sensitiza-
tion to indoor allergens and only an isolated 
finding of an additive interaction for MBzP 
and total IgE at 60 months of age in pre-
dicting eczema was observed. The estimated 
combined effect of an IQR increase in log 
MBzP and a 1–log unit increase in total IgE 
at 60 months of age was slightly greater than 
expected if the effects of MBzP alone and 
log total IgE at 60 months of age alone were 
added. These prospective results extend previ-
ous cross-sectional results nested in a Swedish 
cohort linking house dust concentrations of 
BBzP and eczema in a dose–response manner 
(n = 115 with eczema and n = 177 controls) 
(Bornehag et al. 2004). Although Swedish 
case children 3–8 years of age with physician-
diagnosed eczema had statistically significantly 
higher BBzP concentration in their bedroom 
dust than controls, consistent with the find-
ings here, there was no difference in BBzP 
concentration between atopic and nonatopic 
cases (Bornehag et al. 2004).
One particular strength of the pres-
ent study is the use of a urinary biomarker 
of phthalate exposure that has been shown 
previously in this population to have good 
reproducibility over late pregnancy [intraclass 
correlation coefficient (ICC) = 0.66 for MBzP 
sampled 2–4 times over 6 weeks] (Adibi et al. 
2008). In addition, the prospective birth 
cohort design allows the measure of prenatal 
exposure to precede the development and sub-
sequent report of children’s health outcomes. 
It also has enabled us to evaluate the associa-
tion between prenatal exposure to BBzP and 
early- versus late-onset eczema based on the 
age at first report. When questionnaires asked 
at different ages were analyzed with separate 
models, associations between prenatal urinary 
concentrations of MBzP and eczema had larger 
effect size estimates on questionnaires collected 
at earlier ages than those after 24 months. In 
the multinomial analysis, MBzP concentration 
was associated with early but not late onset 
eczema (first report after 24 months) relative 
to those in the no-eczema group.
Given the known association between 
eczema and atopy, and between eczema and 
cockroach and mouse IgE in the CCCEH 
cohort (Donohue et al. 2008), we also hypoth-
esized that exposure to BBzP would be asso-
ciated with sensitization to the three most 
Figure 2. Association between prenatal urinary concentration of MBzP and report of eczema by 24 months 
from a multivariable logistic regression adjusted with mean specific gravity and sex. The y-axis is shown 
on the logit scale and labeled with the corresponding predicted probabilities. The x-axis is shown on a 
log scale and labeled with the corresponding concentrations. The overall cohort model is shown (black) 
with 95% CI (gray); the exposure distribution for all participants reporting (top) and not reporting (bottom) 
eczema is shown with horizontal box plots. The ethnic subsets are shown in dashed and dotted lines for 
African Americans and Dominicans, with individual observations shown at their urinary concentration as 
triangles and circles, respectively. Although the baseline probabilities differ in the two subsets, the overall 
association remains positive, with increasing urinary concentrations of MBzP.
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common indoor aeroallergens. Experimental 
evidence, at least with other phthalates, sup-
ported this approach. For example, human 
peripheral blood mononuclear cells incu-
bated with DEHP, or its hydrolytic metabo-
lite mono(2-ethylhexyl) phthalate (MEHP), 
produced greater proallergic cytokine levels 
and histamine release [reviewed by Kwak 
et al. (2009)]. In addition, prenatal and neo-
natal exposure of mice to DEHP induced 
an atopic dermatitis-like phenotype in dust 
mite–sensitized offspring and up-regulated 
the expression of the proallergic chemokine 
eotaxin (Yanagisawa et al. 2008). Interestingly, 
another phthalate, di-n-butyl phthalate, 
up-regulated skin hypersensitivity reactions 
via thymic stromal lymphopoietin, a cytokine 
known to activate the maturation of dendritic 
cells and recently associated with eczema, in 
mice (Larson et al. 2010; Shigeno et al. 2009).
However, our findings suggest that expo-
sure to BBzP may increase the risk of eczema 
through a nonallergic mechanism. Although 
eczema is considered frequently an early indi-
cator of IgE-mediated allergic diseases (Leung 
et al. 2004), eczema among non-atopic chil-
dren also is prevalent. Two-thirds of children 
with eczema are nonatopic in population-
based studies (Flohr et al. 2004). In NHANES 
2005–2006, 68% of children 6–10 years of 
age with reported eczema did not have sen-
sitization to indoor allergens, and 36% did 
not have elevated (i.e., > 50 IU/mL) total IgE 
levels (NCHS 2008), compared with 71% 
and 40% respectively at 60 months of age in 
this African-American and Dominican cohort. 
Further, evidence suggests that immuno-
pathogenesis of eczema can be triggered 
by mechanisms both unrelated and related 
to allergic sensitization. For example, trans-
genic mice overexpressing interleukin (IL)–31 
develop eczema-like skin lesions with features 
characteristic of nonatopic dermatitis (lack of 
increased IgE) (Dillon et al. 2004). However, 
additional studies involving stimulation of 
human epidermal keritonocyte cell lines with 
human IL-31 induced the expression of sev-
eral proallergic chemokines, including TARC/
CCL17 (thymus- and activation-regulated 
chemokine) and MDC (macrophage-derived 
chemokine)/CCL22 that are important to the 
recruitment of inflammatory cells to the skin 
(Dillon et al. 2004). The presence of single 
nucleotide polymorphisms in IL-31 in analy-
ses combining data from three independent 
European study populations was linked to 
nonatopic, and not atopic, eczema (Schulz 
et al. 2007). In an in vitro study of the human 
epithelial cell line A549, several phthalate 
metabolites, including MEHP and mono-n-
octyl phthalate, but not MBzP, stimulated 
the production of the nonallergic, proinflam-
matory cytokine IL-8 (Jepsen et al. 2004). 
Finally, in an in vitro study, culture of Cos-1 
cell lines with BBzP upon transfection with 
either the peroxisome proliferator-activated 
receptors (PPAR)α or PPARγ-expressing plas-
mid increased the transcriptional activity of 
both PPARα and PPARγ (Hurst and Waxman 
2003). Mice deficient in the PPARα gene are 
more likely to develop eczema-like skin lesions 
upon antigen sensitization (Staumont-Salle 
et al. 2008), suggesting that the expression 
of this gene is more likely to protect against, 
rather than induce, eczema.
The association between eczema and 
phthalate exposure may vary by race/ethnicity. 
The joint effect of an IQR increase in MBzP 
urinary concentration and African-American 
race/ethnicity resulted in a RR estimate that 
was 0.54 higher (bootstrap 95% CI on RERI: 
–0.07, 1.39) than the expected sum of the 
main effects estimated in the absence of inter-
action, although this additive interaction did 
not reach statistical significance. We speculate 
that differences in dietary patterns as well as 
differences in the prevalence of indoor materi-
als, such as vinyl flooring made with BBzP, 
may contribute to the observed higher uri-
nary concentrations of MBzP among African 
Americans. Differences in eczema prevalence 
by race/ethnicity have been reported in the 
2003 National Survey of Children’s Health; 
9.7% of white-only and 15.9% of black-only 
households reported eczema in the previous 
year for children < 18 years of age (Shaw et al. 
2011). Race remained a significant predic-
tor after controlling for a number of poten-
tial confounders also associated with higher 
eczema such as young child age, higher level 
of education, higher family income, and 
urban residence (Shaw et al. 2011). Among 
children 6–10 years of age included in the 
NHANES 2005–2006 with serum IgE mea-
sures, 4% of Mexican-American respondents 
(n = 12/267), and 22% of African-American 
respondents (n = 45/201) said yes to “Has a 
doctor or other health professional ever told 
you that __ has eczema?” (National Center 
for Health Statistics 2008). The subset of 
Mexican-American participants in NHANES 
may not be an appropriate comparison popu-
lation for Dominican-American families in 
New York City; only 3.3% of NHANES 
respondents were classified as “Hispanic–
Other Hispanic,” thus limiting the ability to 
compare the NHANES estimate with that for 
our Dominican population in New York City. 
In addition, the NHANES estimate was for an 
older group of children.
We acknowledge several limitations. 
There was no assessment of postnatal expo-
sure to phthalates. Child eczema was assessed 
via questionnaire and therefore subject to a 
lack of standardization, misclassification, or 
recall bias. The lack of consistent reporting of 
eczema after the first report of ever-eczema 
may indicate some misclassification. However, 
our query “Has your doctor ever said that your 
child has eczema?” has been validated by phy-
sician diagnosis in a study of Oregon school 
children (Laughter et al. 2000). Because the 
question specifically asked about doctor-diag-
nosed eczema, misclassification also could be 
associated with access to health care, although 
it is unclear how access to health care could 
be related to phthalate exposure. Also there is 
no reason to believe that any misclassification 
would be differential by phthalate exposure 
and thus should only bias the effect estimates 
toward the null. Furthermore, the main asso-
ciation did not differ between consistent and 
inconsistent reporters of ever-eczema in the 
sensitivity analyses. Some of the differences 
in the report of eczema by ethnicity may par-
tially reflect differences in the understanding 
of what constitutes “eczema,” although there 
were no differences in report between English- 
and Spanish-speaking Dominican partici-
pants. In addition, the contribution of food 
allergy to MBzP-associated early eczema was 
not assessed, and the higher total IgE among 
those with eczema than those without eczema 
suggests that sensitization to unmeasured aller-
gens might be associated with eczema here. A 
larger suite of specific IgEs (anti-cockroach, 
dust mite, mouse, cat, dog, tree, grass, rag-
weed, and mold) were tested at 7 years of age 
in this cohort and were available for compari-
son with 197 children in this analysis. Among 
these children, 25% (50/197) were classified as 
sensitized to indoor allergens (cockroach, dust 
mite, or mouse) by 5 years, whereas at 7 years 
this proportion increased to 34% (67/197). 
Expanding to a definition of any indoor or 
outdoor IgEs at 7 years of age, 46% (90/197) 
would be classified as seroatopic. Thus, in a 
subset with data through age 7 years, the use of 
specific IgE to cockroach, dust mite, or mouse 
to characterize sensitization to indoor allergens 
underestimates the proportion of children with 
any common indoor or outdoor allergic sensi-
tization by about one-quarter (23/90). We also 
cannot rule out that children classified as not 
sensitized to indoor allergens may later develop 
sensitization. Although sensitization to indoor 
allergens is not the same as any seroatopy, the 
consistency between results using sensitiza-
tion to any of three indoor specific IgEs and 
continuous total IgE concentration suggests 
this is not a major concern. Rates of sensitiza-
tion differed at 24 months, although not at 36 
or 60 months, among participants included 
versus excluded from the analysis, raising a 
small possibility of bias. However, baseline 
characteristics of participants included versus 
excluded from analysis were otherwise very 
similar, likely because 94% of those excluded 
lacked the prenatal urine sample for phthalates 
added after the initiation of the cohort and 
unlikely to be systematically associated with 
exposure or outcomes.
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Conclusions
Using a longitudinal urban U.S. birth cohort, 
we found novel results that suggest that MBzP 
urinary concentrations measured prenatally 
are associated with early-onset eczema. This 
finding seemed unrelated to sensitization to 
common indoor allergens or total IgE. Future 
intervention studies may test whether early-
life exposure to BBzP can be reduced and 
whether this leads to a reduction in eczema, a 
very common childhood disease.
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